Figure 2 Kaplan-Meier Curves for event-free survival between treatment groupsFigure displays Kaplan-Meier survival curves comparing event-free survival between patients receiving oral anticoagulation (OAC) alone (group 1) and those receiving both OAC and antiplatelet therapy (APT) (group 2). Panel A illustrates the composite endpoint – which includes massive gastrointestinal bleeding, stroke, revascularization, and cardiovascular mortality – demonstrating a non-significant trend of worse event-free survival in group 2 (log-rank P=0.06). Panel B focuses specifically on revascularization-free survival, showing a similar trend toward worse outcomes in group 2. Although the difference did not reach statistical significance (log-rank P=0.08), the curve suggests a clinically relevant increase in revascularization events over the follow-up period in patients treated with dual therapy.